NASDAQ:SNTS Santarus (SNTS) Stock Price, News & Analysis → Watch this FREE trading tutorial while it’s still available (From InvestorPlace) (Ad) Free SNTS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range$16,995.00▼$16,995.0052-Week Range N/AVolume54,432 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Santarus alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Santarus Stock (NASDAQ:SNTS)Santarus, Inc. (Santarus) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists. As of December 31, 2012, the Company’s marketed and approved products included Uceris (budesonide), Zegerid (omeprazole/sodium bicarbonate), Glumetza (metformin hydrochloride extended release tablets), Cycloset (bromocriptine mesylate) tablets and Fenoglide (fenofibrate) tablets. As of December 31, 2012, the Company’s investigational drugs included Ruconest (recombinant human C1 esterase inhibitor), Rifamycin SV MMX, and SAN-300 (anti-VLA-1 antibody). In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.Read More Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. SNTS Stock News HeadlinesFebruary 23, 2024 | morningstar.comSociete Nationale des Telecommunications SONATEL SNTSDecember 30, 2023 | mirror.co.ukAnt McPartlin and wife Anne-Marie beam as they jet off to Dubai for plush New Year holidayMay 4, 2024 | Weiss Ratings (Ad)FW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.December 18, 2023 | bbc.comJack Ma's Ant Group: World's biggest market debut suspendedOctober 12, 2023 | thestreet.comBiotech Stock Mailbag: Cardium TherapeuticsJuly 27, 2023 | investing.comSociete Nationale des Telecommunications du Senegal (SNTS)May 25, 2023 | wsj.comSociete Nationale de Telecommunications du SenegalFebruary 17, 2023 | duluthnewstribune.comSaints report: Bostedt, CSS win their sixth straight in men’s hockeyMay 4, 2024 | Weiss Ratings (Ad)FW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.February 14, 2023 | duluthnewstribune.comSaints report: CSS earn MIAC men’s hockey sweep of CobbersFebruary 14, 2023 | duluthnewstribune.comSaints report: CSS men victorious at AugsburgDecember 26, 2022 | thestreet.comSantarus Stock Hits New 52-Week High (SNTS)September 20, 2022 | usatoday.comTampa Bay Buccaneers at New Orleans Saints: Predictions, picks and odds for NFL Week 2 matchupAugust 22, 2022 | thestreet.comCramer's 'Mad Money' Recap: The Knot Worth TyingAugust 22, 2022 | thestreet.com5 Stocks Insiders are Buying This WeekSee More Headlines Receive SNTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Santarus and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SNTS CUSIP80281730 CIK1172480 Webwww.santarus.com Phone+1-858-3145700FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report SNTS Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Santarus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Santarus investors own include Baidu (BIDU), Home Depot (HD), Pharmacyclics (PCYC), Yelp (YELP), ACADIA Pharmaceuticals (Acad), Altaba (AABA), Allergan (AGN), Alexion Pharmaceuticals (ALXN) and Cree (CREE). This page (NASDAQ:SNTS) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchStock-Picking AI Predicts #1 Stock of 2024AltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Santarus Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.